Generation Bio, Vir partner for mAbs against COVID-9

By The Science Advisory Board staff writers

March 30, 2020 -- Generation Bio and Vir Biotechnology have agreed to collaborate on research into the use of monoclonal antibodies against the SARS-CoV-2 virus that causes COVID-19.

The collaboration will allow Generation Bio's gene therapy platform, which delivers genetic information to cells without the use of adeno-associated viruses, to be combined with Vir's neutralizing antibodies, the two firms said.

Vir's leading antibody was developed from a patient who recovered from SARS-CoV-1 and could neutralize SARS-CoV-2, according to Generation Bio and Vir.


Copyright © 2020 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.